Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP

Telix Pharmaceuticals (ASX:TLX) finalized the acquisition of QSAM Biosciences and its lead investigational drug Samarium-153-DOTMP, according to a Friday filing with the Australian Securities Exchange

MT NewswiresMay 3 07:50

Bell Potter Downgrades Telix Pharmaceuticals Ltd. (TLPPF) to a Hold

TipRanksMay 1 09:35

Telix Pharmaceuticals Cut to Hold From Buy by Bell Potter >TLX.AU

Telix Pharmaceuticals Cut to Hold From Buy by Bell Potter >TLX.AU

Dow JonesMay 1 08:17

Bell Potter Downgrades Telix Pharmaceuticals to Hold From Buy, Price Target Is AU$14.50

Telix Pharmaceuticals (ASX:TLX) has an average rating of buy and price targets ranging from AU$13.52 to AU$19.30, according to analysts polled by CapitalIQ. Price (AUD): $15.28, Change: $-0.23, Percen

MT NewswiresApr 30 09:35

Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Telix Pharmaceuticals Ltd. (OtherTLPPF) and Intuitive Surgical (ISRG)

TipRanksApr 23 17:40

Jarden Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)

TipRanksApr 22 15:05